Teacher Retirement System of Texas Has $499,000 Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Teacher Retirement System of Texas grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 18.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,176 shares of the biopharmaceutical company’s stock after purchasing an additional 2,361 shares during the quarter. Teacher Retirement System of Texas’ holdings in Agios Pharmaceuticals were worth $499,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Intech Investment Management LLC increased its position in Agios Pharmaceuticals by 40.7% during the fourth quarter. Intech Investment Management LLC now owns 28,248 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 8,170 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Agios Pharmaceuticals by 11.7% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 32,790 shares of the biopharmaceutical company’s stock worth $1,082,000 after purchasing an additional 3,430 shares during the period. Swiss National Bank raised its position in shares of Agios Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company’s stock valued at $3,311,000 after buying an additional 1,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Agios Pharmaceuticals by 464.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,678 shares of the biopharmaceutical company’s stock valued at $4,130,000 after buying an additional 103,405 shares during the period. Finally, AlphaQuest LLC grew its position in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 2,338 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

AGIO opened at $29.30 on Tuesday. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of 2.58 and a beta of 0.90. The firm’s 50-day simple moving average is $33.11 and its 200-day simple moving average is $40.71. Agios Pharmaceuticals, Inc. has a twelve month low of $27.14 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AGIO shares. Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.57.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.93% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.